Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203 - Concepedia

Concepedia

Publication | Open Access

Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203

DOI Full Paper Access

216

Citations

21

References

2010

Year

Weijing Sun, Mark Powell, Peter J. O’Dwyer, Paul J. Catalano, Rafat Ansari, Al B. Benson

Journal of Clinical Oncology

Abstract

The combination of sorafenib, docetaxel, and cisplatin has an encouraging efficacy profile with tolerable toxicity. Additional studies of sorafenib with chemotherapy are warranted in gastric cancer.

References

	Year	Citations

Page 1